PharmaCyte Biotech, Inc. (PMCB) - Q1 2025 (Ended July 31, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 31, 2024. PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer using its proprietary "Cell-in-a-Box" technology. The company's primary product candidate, CypCaps, is intended for locally advanced, inoperable pancreatic cancer (LAPC). The company is currently a smaller reporting company and is not an emerging growth company.
Key Financial Metrics
| Metric | Q1 2024 (Ended July 31) | Q1 2023 (Ended July 31) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income (Loss) | $23,421,355 | $(3,183,297) |
| Net Income Attributable to Common Stockholders | $20,587,507 | $(6,775,179) |
| Operating Expenses | $1,268,887 | $2,075,326 |
| Cash and Cash Equivalents (End of Period) | $32,635,092 | $74,662,527 |
| Total Assets | $70,194,434 | $79,880,485 (Restated) |
| Total Liabilities | $17,152,950 | $40,686,377 (Restated) |
| Stockholders' Equity | $47,708,370 | $39,193,789 (Restated) |
Note: Q1 2023 figures have been restated due to accounting errors regarding preferred stock accretion (see Material Changes).
Material Changes vs. Prior Period
- Net Income Surge: The company reported a net income of $23.4 million compared to a net loss of $3.2 million in the prior year. This turnaround is primarily driven by non-cash gains totaling approximately $24.7 million, including a $21.4 million gain on a related-party investment in TNF Pharmaceuticals and favorable changes in the fair value of warrant and derivative liabilities.
- Operating Expense Reduction: Total operating expenses decreased by approximately $806,000 (39%) to $1.27 million. This reduction is largely due to the absence of $913,640 in warrant issuance costs incurred in the prior year, partially offset by increases in compensation and director fees.
- Cash Position: Cash and cash equivalents decreased by $17.5 million to $32.6 million. The decline was driven by a $7.0 million investment in TNF Pharmaceuticals, $9.4 million in preferred stock redemptions, and $0.7 million in common stock repurchases.
- Restatement of Prior Period: The company restated its Q1 2023 financials to correct the omission of preferred stock accretion and misclassification of dividends. This adjustment increased the reported net loss for Q1 2023 from $(3.5) million to $(6.8) million attributable to common stockholders.
Outlook, Risks, and Management Commentary
- FDA Clinical Hold: The company's Investigational New Drug (IND) application for LAPC remains on clinical hold since October 2020. Management is actively addressing FDA requests, including additional sequencing data, stability studies, and biocompatibility assessments. Spending on development programs has been curtailed pending a review by the Board's Business Review Committee.
- Strategic Review: The Board is reviewing the company's relationship with SG Austria, the licensor of the Cell-in-a-Box technology, noting that licensed patents have expired and know-how resides solely with SG Austria. A new framework for this relationship is being sought.
- Liquidity: Management believes current cash balances of approximately $32.6 million are sufficient to fund operations for at least the next 12 months. However, the company may need to raise additional capital for future projects, which could be dilutive.
- Legal Proceedings: The company is defending against a breach of contract lawsuit filed by H.C. Wainwright & Co., LLC, seeking damages of at least $1.95 million plus warrants. Management does not believe a loss is reasonably probable at this time.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding insufficient segregation of duties and management review controls.
Investor Verification Checklist
- Investment Gain Sustainability: Verify the nature and realizability of the $21.4 million gain on the TNF Pharmaceuticals investment, which drove the quarter's profitability.
- FDA Clinical Hold Status: Confirm the current status of the FDA clinical hold and the timeline for lifting it, as this is critical for the company's primary revenue-generating asset.
- SG Austria Relationship: Assess the outcome of the Board's review of the SG Austria partnership and the potential impact on the company's proprietary technology rights.
- Preferred Stock Redemption: Monitor the cash outflow required for the remaining Series B convertible preferred stock redemptions and the associated dividend accruals.
- Internal Control Remediation: Review the company's plan to remediate the identified material weaknesses in internal controls over financial reporting.